Top

Published in:

01-06-2011 | Review

Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences

Authors: Hakan Cam, Peter J. Houghton

Published in: Targeted Oncology | Issue 2/2011

Abstract

Integration of cellular and extracellular signals maintains tissue homeostasis under conditions of normal proliferation and stress. A central player in regulating responses to stress is the serine/threonine kinase mammalian target of rapamycin (mTOR). In many cancers, mTOR complex 1 (mTORC1) signaling is enhanced, even under conditions where such signaling should be suppressed. This article reviews some of the details that are emerging on how low oxygen (hypoxia) regulates mTORC1 signaling, and the consequences for dysregulation in pediatric solid tumors.

De Virgilio C, Loewith R (2006) The TOR signalling network from yeast to man. Int J Biochem Cell Biol 38(9):1476–1481. doi:10.1016/j.biocel.2006.02.013 PubMedCrossRef

Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510. doi:10.1038/onc.2008.245 PubMedCrossRef

Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12(1):9–22. doi:10.1016/j.ccr.2007.05.008 PubMedCrossRef

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRef

Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9(4):138–141PubMedCrossRef

Petricoin EF 3rd, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ Jr, Qualman S, Tsokos M, Krishnan K, Helman LJ, Liotta LA (2007) Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67(7):3431–3440. doi:10.1158/0008-5472.CAN-06-1344 PubMedCrossRef

Wan X, Helman LJ (2007) The biology behind mTOR inhibition in sarcoma. Oncologist 12(8):1007–1018. doi:10.1634/theoncologist.12-8-1007 PubMedCrossRef

Arsham AM, Howell JJ, Simon MC (2003) A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278(32):29655–29660. doi:10.1074/jbc.M212770200 PubMedCrossRef

Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18(23):2893–2904. doi:10.1101/gad.1256804 PubMedCrossRef

10.

DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22(2):239–251. doi:10.1101/gad.1617608 PubMedCrossRef

11.

Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP (2006) PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442(7104):779–785. doi:10.1038/nature05029 PubMedCrossRef

12.

Li Y, Wang Y, Kim E, Beemiller P, Wang CY, Swanson J, You M, Guan KL (2007) Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J Biol Chem 282(49):35803–35813. doi:10.1074/jbc.M705231200 PubMedCrossRef

13.

Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8(11):851–864. doi:10.1038/nrc2501 PubMedCrossRef

14.

Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3):180–192. doi:10.1038/nrc2344 PubMedCrossRef

15.

Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3(3):155–168. doi:10.1038/nrc1011 PubMedCrossRef

16.

Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408(6811):433–439. doi:10.1038/35044005 PubMedCrossRef

17.

Durocher D, Jackson SP (2001) DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 13(2):225–231PubMedCrossRef

18.

Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y (2003) Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 22(20):5612–5621. doi:10.1093/emboj/cdg541 PubMedCrossRef

19.

Lee JH, Paull TT (2005) ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308(5721):551–554. doi:10.1126/science.1108297 PubMedCrossRef

20.

Goldberg M, Stucki M, Falck J, D’Amours D, Rahman D, Pappin D, Bartek J, Jackson SP (2003) MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 421(6926):952–956. doi:10.1038/nature01445 PubMedCrossRef

21.

Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ (2003) MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421(6926):961–966. doi:10.1038/nature01446 PubMedCrossRef

22.

Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421(6922):499–506. doi:10.1038/nature01368 PubMedCrossRef

23.

Andegeko Y, Moyal L, Mittelman L, Tsarfaty I, Shiloh Y, Rotman G (2001) Nuclear retention of ATM at sites of DNA double strand breaks. J Biol Chem 276(41):38224–38230. doi:10.1074/jbc.M102986200 PubMed

24.

Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281(5383):1677–1679PubMedCrossRef

25.

Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ (2000) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97(19):10389–10394. doi:10.1073/pnas.190030497 PubMedCrossRef

26.

Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286(5442):1162–1166PubMedCrossRef

27.

Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ (2001) ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276(45):42462–42467. doi:10.1074/jbc.C100466200 PubMedCrossRef

28.

Bencokova Z, Kaufmann MR, Pires IM, Lecane PS, Giaccia AJ, Hammond EM (2009) ATM activation and signaling under hypoxic conditions. Mol Cell Biol 29(2):526–537. doi:10.1128/MCB.01301-08 PubMedCrossRef

29.

Cam H, Easton JB, High A, Houghton PJ (2010) mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. Mol Cell 40(4):509–520. doi:10.1016/j.molcel.2010.10.030 PubMedCrossRef

30.

Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035):864–870. doi:10.1038/nature03482 PubMedCrossRef

31.

Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40(2):179–204. doi:10.1016/j.molcel.2010.09.019 PubMedCrossRef

32.

Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, Inoki K, Guan KL, Shen J, Person MD, Kusewitt D, Mills GB, Kastan MB, Walker CL (2010) ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 107(9):4153–4158. doi:10.1073/pnas.0913860107 PubMedCrossRef

33.

Freiberg RA, Hammond EM, Dorie MJ, Welford SM, Giaccia AJ (2006) DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol Cell Biol 26(5):1598–1609. doi:10.1128/MCB.26.5.1598-1609.2006 PubMedCrossRef

34.

Hunt CR, Pandita RK, Laszlo A, Higashikubo R, Agarwal M, Kitamura T, Gupta A, Rief N, Horikoshi N, Baskaran R, Lee JH, Lobrich M, Paull TT, Roti Roti JL, Pandita TK (2007) Hyperthermia activates a subset of ataxia-telangiectasia mutated effectors independent of DNA strand breaks and heat shock protein 70 status. Cancer Res 67(7):3010–3017. doi:10.1158/0008-5472.CAN-06-4328 PubMedCrossRef

35.

Schofield CJ, Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5(5):343–354. doi:10.1038/nrm1366 PubMedCrossRef

36.

Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275(33):25733–25741. doi:10.1074/jbc.M002740200 PubMedCrossRef

37.

Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294(5545):1337–1340. doi:10.1126/science.1066373 PubMedCrossRef

38.

Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107(1):43–54PubMedCrossRef

39.

Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F (2004) JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118(6):781–794. doi:10.1016/j.cell.2004.08.025 PubMedCrossRef

40.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292(5516):464–468. doi:10.1126/science.105981 PubMedCrossRef

41.

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516):468–472. doi:10.1126/science.1059796 PubMedCrossRef

42.

Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, Kadoya T, Erdjument-Bromage H, Tempst P, Frappell PB, Bowtell DD, Ronai Z (2004) Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 117(7):941–952. doi:10.1016/j.cell.2004.06.001 PubMedCrossRef

43.

Brahimi-Horn C, Mazure N, Pouyssegur J (2005) Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 17(1):1–9. doi:10.1016/j.cellsig.2004.04.010 PubMedCrossRef

44.

Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F, Arzt E (2007) RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131(2):309–323. doi:10.1016/j.cell.2007.07.044 PubMedCrossRef

45.

Cheng J, Kang X, Zhang S, Yeh ET (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131(3):584–595. doi:10.1016/j.cell.2007.08.045 PubMedCrossRef

46.

Gao X, Pan D (2001) TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 15(11):1383–1392. doi:10.1101/gad.901101 PubMedCrossRef

47.

Potter CJ, Huang H, Xu T (2001) Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105(3):357–368PubMedCrossRef

48.

Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4(9):648–657. doi:10.1038/ncb839 PubMedCrossRef

49.

Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10(1):151–162PubMedCrossRef

50.

Li Y, Inoki K, Vacratsis P, Guan KL (2003) The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J Biol Chem 278(16):13663–13671. doi:10.1074/jbc.M300862200 PubMedCrossRef

51.

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101(37):13489–13494. doi:10.1073/pnas.0405659101 PubMedCrossRef

52.

Corradetti MN, Inoki K, Guan KL (2005) The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 280(11):9769–9772. doi:10.1074/jbc.C400557200 PubMedCrossRef

53.

Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101(10):3329–3335. doi:10.1073/pnas.0308061100 PubMedCrossRef

54.

Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC (2006) Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21(4):521–531. doi:10.1016/j.molcel.2006.01.010 PubMedCrossRef

55.

Reiling JH, Hafen E (2004) The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev 18(23):2879–2892. doi:10.1101/gad.322704 PubMedCrossRef

56.

Vega-Rubin-de-Celis S, Abdallah Z, Kinch L, Grishin NV, Brugarolas J, Zhang X (2010) Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry 49(11):2491–2501. doi:10.1021/bi902135e PubMedCrossRef

57.

Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA (2002) REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 10(5):995–1005PubMedCrossRef

58.

Wang Z, Malone MH, Thomenius MJ, Zhong F, Xu F, Distelhorst CW (2003) Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals. J Biol Chem 278(29):27053–27058. doi:10.1074/jbc.M303723200 PubMedCrossRef

59.

Houghton PJ, Huang S (2004) mTOR as a target for cancer therapy. Curr Top Microbiol Immunol 279:339–359PubMedCrossRef

60.

Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471–484. doi:10.1016/j.cell.2006.01.016 PubMedCrossRef

61.

Connolly E, Braunstein S, Formenti S, Schneider RJ (2006) Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 26(10):3955–3965. doi:10.1128/MCB.26.10.3955-3965.2006 PubMedCrossRef

62.

Kaper F, Dornhoefer N, Giaccia AJ (2006) Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res 66(3):1561–1569. doi:10.1158/0008-5472.CAN-05-3375 PubMedCrossRef

63.

Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560):88–91. doi:10.1038/379088a0 PubMedCrossRef

64.

Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC (2010) Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 18(6):619–629. doi:10.1016/j.ccr.2010.10.034 PubMedCrossRef

Title: Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences
Authors: Hakan Cam
Peter J. Houghton
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 2/2011
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-011-0173-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

Common toxicities of mammalian target of rapamycin inhibitors

Are we ready to move away from nature? The rapamycin story

Keynote webinar | Spotlight on antibody–drug conjugates in cancer